Related references
Note: Only part of the references are listed.Dopamine agonist resistant prolactinomas: any alternative medical treatment?
P. Souteiro et al.
PITUITARY (2020)
Expression patterns of ERα66 and its novel variant isoform ERα36 in lactotroph pituitary adenomas and associations with clinicopathological characteristics
Fatemeh Mahboobifard et al.
PITUITARY (2020)
Epidemiology and Management Challenges in Prolactinomas
Laurent Vroonen et al.
NEUROENDOCRINOLOGY (2019)
The role and mechanisms of action of microRNAs in cancer drug resistance
Wengong Si et al.
CLINICAL EPIGENETICS (2019)
miR-93-5p targets Smad7 to regulate the transforming growth factor-β1/Smad3 pathway and mediate fibrosis in drug-resistant prolactinoma
Bin Hu et al.
BRAIN RESEARCH BULLETIN (2019)
MiR-137's Tumor Suppression on Prolactinomas by Targeting MITF and Modulating Wnt Signaling Pathway
Cao Lei et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
MiR-1299 promotes the synthesis and secretion of prolactin by inhibiting FOXO1 expression in drug-resistant prolactinomas
Zheng Xiao et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
DEPTOR inhibits cell proliferation and confers sensitivity to dopamine agonist in pituitary adenoma
Hong Yao et al.
CANCER LETTERS (2019)
Roles of differential expression of miR-543-5p in GH regulation in rat anterior pituitary cells and GH3 cells
Ze-Wen Yu et al.
PLOS ONE (2019)
Management of Dopamine Agonist-Resistant Prolactinoma
Dominique Maiter
NEUROENDOCRINOLOGY (2019)
Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1
M. Jian et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2019)
The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
Xiaoshuang Liu et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Clinical management of difficult to treat macroprolactinomas
Nicolas Sahakian et al.
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM (2019)
Role of TGF-β1/Smad3-mediated fibrosis in drug resistance mechanism of prolactinoma
Bin Hu et al.
BRAIN RESEARCH (2018)
Emerging microRNAs in cancer diagnosis, progression, and immune surveillance
Amani M. Harrandah et al.
CANCER LETTERS (2018)
MiR-30a: A Novel Biomarker and Potential Therapeutic Target for Cancer
Lin-hong Jiang et al.
JOURNAL OF ONCOLOGY (2018)
Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas
Hai Yan Huang et al.
ENDOCRINE (2018)
The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine
Allyson K. Roof et al.
ENDOCRINOLOGY (2018)
被撤回的出版物: Inhibition of microRNA-200a Upregulates the Expression of Striatal Dopamine Receptor D2 to Repress Apoptosis of Striatum via the cAMP/PKA Signaling Pathway in Rats with Parkinson's Disease (Retracted article. See vol. 55, pg. 675, 2021)
Dong-Mei Wu et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment
C. B. F. Bueno et al.
PITUITARY (2017)
MicroRNA-9 regulates fetal alcohol-induced changes in D2 receptor to promote prolactin production
Omkaram Gangisetty et al.
JOURNAL OF ENDOCRINOLOGY (2017)
MicroRNAs in pituitary tumors
Anne Wierinckx et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2017)
The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas
M. Victoria Recouvreux et al.
JOURNAL OF ENDOCRINOLOGY (2016)
MicroRNAs in the pituitary
Erica Gentilin et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Evidence for MicroRNA-Mediated Regulation of Steroidogenesis by Hypoxia
Richard Man Kit Yu et al.
ENVIRONMENTAL SCIENCE & TECHNOLOGY (2015)
Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth
Etienne Delgrange et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas
Zhenye Li et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2015)
Rapid Communication: A MicroRNA-132/212 Pathway Mediates GnRH Activation of FSH Expression
Jerome Lannes et al.
MOLECULAR ENDOCRINOLOGY (2015)
Deregulation of miR-183 and KIAA0101 in aggressive and malignant pituitary tumors
Magali Roche et al.
FRONTIERS IN MEDICINE (2015)
MiR-142-3p represses TGF-β-induced growth inhibition through repression of TGFβR1 in non-small cell lung cancer
Zhe Lei et al.
FASEB JOURNAL (2014)
MicroRNA-9 and MicroRNA-326 Regulate Human Dopamine D2 Receptor Expression, and the MicroRNA-mediated Expression Regulation Is Altered by a Genetic Variant
Sandra Shi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Management of medically refractory prolactinoma
Mark E. Molitch
JOURNAL OF NEURO-ONCOLOGY (2014)
Dopamine receptor D2S gene transfer improves the sensitivity of GH3 rat pituitary adenoma cells to bromocriptine
Qiang Li et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2014)
MicroRNA expression profile of bromocriptine-resistant prolactinomas
Zhe Bao Wu et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2014)
MicroRNA 375 Mediates the Signaling Pathway of Corticotropin-releasing Factor (CRF) Regulating Pro-opiomelanocortin (POMC) Expression by Targeting Mitogen-activated Protein Kinase 8
Nan Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Transcriptional cooperation between p53 and NF-κB p65 regulates microRNA-224 transcription in mouse ovarian granulosa cells
Meng Liang et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2013)
Each Individual Isoform of the Dopamine D2 Receptor Protects from Lactotroph Hyperplasia
Daniela Radl et al.
MOLECULAR ENDOCRINOLOGY (2013)
Differentially Expressed miRNAs after GnRH Treatment and Their Potential Roles in FSH Regulation in Porcine Anterior Pituitary Cell
Rui-Song Ye et al.
PLOS ONE (2013)
Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels
Satoko Shimazu et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Altered MicroRNA Expression Profile in Human Pituitary GH Adenomas: Down-Regulation of miRNA Targeting HMGA1, HMGA2, and E2F1
Daniela D'Angelo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis
D. Palmieri et al.
ONCOGENE (2012)
microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment
Chengde Wang et al.
ONCOLOGY REPORTS (2012)
miRNAs and estrogen action
Carolyn M. Klinge
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2012)
Active and Total Transforming Growth Factor-β1 Are Differentially Regulated by Dopamine and Estradiol in the Pituitary
M. Victoria Recouvreux et al.
ENDOCRINOLOGY (2011)
Resistant prolactinomas
V. Vasilev et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2011)
Dopamine agonist-resistant prolactinomas
Michael C. Oh et al.
JOURNAL OF NEUROSURGERY (2011)
miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-α in human breast cancer cells
R. Spizzo et al.
CELL DEATH AND DIFFERENTIATION (2010)
Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior
Zhe Bao Wu et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
MicroRNA-224 Is Involved in Transforming Growth Factor-β-Mediated Mouse Granulosa Cell Proliferation and Granulosa Cell Function by Targeting Smad4
Guidong Yao et al.
MOLECULAR ENDOCRINOLOGY (2010)
Genes Differentially Expressed in Prolactinomas Responsive and Resistant to Dopamine Agonists
Vanessa Q. Passos et al.
NEUROENDOCRINOLOGY (2009)
Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas
M. Filopanti et al.
PHARMACOGENOMICS JOURNAL (2008)
PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes
Carolina Cristina et al.
MOLECULAR CANCER (2007)
Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA
Anwar Hossain et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Advances in the treatment of prolactinomas
Mary P. Gillam et al.
ENDOCRINE REVIEWS (2006)
Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy
E Delgrange et al.
CLINICAL ENDOCRINOLOGY (2006)
miR-15a and miR-16-1 down-regulation in pituitary adenomas
A Bottoni et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2005)
Ethanol and estradiol modulate alternative splicing of dopamine D2 receptor messenger RNA and abolish the inhibitory action of bromocriptine on prolactin release from the pituitary gland
S Oomizu et al.
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH (2003)
Control of lactotrop proliferation by dopamine: Essential role of signaling through D2 receptors and ERKs
C Iaccarino et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Share Paper
